SMARCA4 and neoplasm: Clinical studies of primary prostate tumours reported an overall increase in BRG1 protein by immunohistochemistry [42–46], and increased SMARCA4 gene expression has been reported in tumours from The Cancer Genome Atlas (TCGA) prostate cancer cohort compared to normal prostate tissue [49, 50].